Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of V116 Pneumococcal Vaccine in Adults
NCT04168190Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2019
- Primary completion
- Jul 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of pneumococcal 21-valent conjugate vaccine in Pneumococcal pneumonia (PP), invasive pneumococcal disease (IPD), sponsored by Merck & Co.. Started Dec 2019; status: completed.
02
Drugs
pneumococcal 21-valent conjugate vaccine
03
Conditions
Pneumococcal pneumonia (PP)invasive pneumococcal disease (IPD)
Beyond the preview
Go deeper on NCT04168190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04168190.